Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521923

SCHEMBL1521923

SCHEMBL1521923

CNc1cc2c(cn1)CN(c1cc(NC(=O)Nc3cc(C(C)(C)C)on3)c(F)cc1C)C(=O)N2C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAF1 P04049 5/20 0.41
▸ MAPK3 P27361 2/20 0.41
▸ CSF1R P07333 1/20 0.41
▸ MAPK14 Q16539 4/20 0.40
▸ MAPK13 O15264 1/20 0.38
▸ BRAF P15056 4/20 0.38
▸ FLT3 P36888 2/20 0.38
▸ RET P07949 1/20 0.37
▸ KRAS P01116 2/20 0.37
▸ KDR P35968 2/20 0.37
▸ MAP2K2 P36507 2/20 0.37
▸ MAP2K1 Q02750 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MAPT P10636 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521888 0.90 RAB9A (0.45) RAB9ANPC1RAF1MAPK3CSF1R
SCHEMBL1521732 0.90 BRAF (0.47) RAF1MAPK14MAPK13BRAFRET
SCHEMBL1521500 0.88 RAB9A (0.42) RAB9ANPC1RAF1MAPK3CSF1R
SCHEMBL1521633 0.87 RAB9A (0.43) RAB9ANPC1RAF1MAPK3CSF1R
SCHEMBL1521874 0.84 BRAF (0.36) RAF1MAPK14MAPK13BRAFKRAS
SCHEMBL1521511 0.83 BRAF (0.35) RAF1MAPK14BRAFKRASKDR
SCHEMBL4273911 0.81 RAB9A (0.43) RAB9ANPC1RAF1MAPK3CSF1R
SCHEMBL1521517 0.81 ABL1 (0.44) RAB9ANPC1MAPK14RETKDR
SCHEMBL4272236 0.80 RAB9A (0.44) RAB9ANPC1RAF1MAPK3CSF1R
SCHEMBL1521554 0.80 BRAF (0.48) RAF1MAPK14MAPK13BRAFRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 RAB9A 1244/4885NPC1 4287/4885RAF1 3/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 RAB9A 1244/4885NPC1 4287/4885RAF1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.